Novartis Sucessful 1st Batch of H1N1 Flu Vaccine

Switzerland's Novartis said today it expects to have full production of H1N1 flu vaccine ready by September or October after successfully developing a 1st batch of the vaccine weeks ahead of schedule. Clinical trials will commence next month.

Novartis trades as an ADR, symbol NVS.

The company said it expects to be producing millions of dossages on a weekly basis.